In addition, Tregs have been shown to suppress anticancer immune responses against autologous and tumor-expressing antigens by inhibiting the activation and differentiation of CD4+ helper and CD8+ cytotoxic T cells, thus contributing to tumor occurrence and progression (101, 102). This evidence concerns the gene CD4 and neoplasm.